In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data for the company’s cell therapy for corneal endothelial disease.

Background/aims To study human corneal endothelial cells (HCECs) cultured in vitro with human serum (HS) supplemented media (HS-SM) compared with HCEC cultured in fetal bovine serum (FBS) supplemented ...

Research is underway to develop alternative treatments for corneal endothelial diseases, which are less dependent on the availability of allogeneic tissues – regenerative medicine and cell-based ...

Monocytes are circulating leukocytes of innate immunity derived from the bone marrow that interact with endothelial cells under physiological or pathophysiological conditions to orchestrate ...

SING IMT improved distance and near vision in AMD patients, with minimal impact on corneal endothelial cell density and manageable safety outcomes. At 6 months post-surgery, 97.1% of patients achieved ...

FECD affects the corneal endothelial cells, which form a layer responsible for controlling fluid balance in the cornea. When these cells are lost more quickly than usual in people with FECD ...

Endothelial cells are, by number, one of the most abundant cell types in the heart and active players in cardiac physiology and pathology. Coronary angiogenesis plays a vital role in maintaining ...

Request permissions for this article.

Corrected near visual acuity also improved by approximately three lines after surgery ... with the mean change in corneal endothelial cell density at six months being -280.7 cells/mm².